Literature DB >> 3287971

Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin.

S E Wilson1, J A Boswick, R J Duma, R M Echols, J G Jemsek, R Lerner, R T Lewis, A Z Najem, R A Press, M S Rittenbury.   

Abstract

Three broad-spectrum cephalosporins (cefotetan, moxalactam, and cefoxitin) proved effective in this randomized, prospective trial for treatment of 303 surgical patients with moderately severe regional peritonitis.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3287971     DOI： 10.1016/s0002-9610(88)80215-0

Source DB:  PubMed          Journal:  Am J Surg        ISSN： 0002-9610            Impact factor:   2.565


  8 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

2.  Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.

Authors:  J A Bosso; R A Prince
Journal:  Tex Heart Inst J       Date:  1990

Review 3.  Current antimicrobial therapy of anaerobic infections.

Authors:  C V Sanders; K E Aldridge
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

4.  Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections.

Authors:  M E Falagas; L Barefoot; J Griffith; R Ruthazar; D R Snydman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

Review 5.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

Review 6.  Piperacillin/tazobactam in the treatment of polymicrobial infections.

Authors:  S L Gorbach
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

7.  Cefotetan: a second-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

Authors:  M J Gribble
Journal:  CMAJ       Date:  1994-09-01       Impact factor: 8.262

8.  In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial.

Authors:  Adam G Stewart; Kyra Cottrell; Andrew Henderson; Kanthi Vemuri; Michelle J Bauer; David L Paterson; Patrick N A Harris
Journal:  Microbiol Spectr       Date:  2021-07-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.